0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha L beta 2

Integrin alpha L beta 2

Brief Information

Name:Integrin alpha-L/beta-2 (LFA-1)
Target Synonym:Lymphocyte Function-Associated Antigen-1
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
IT2-H53W3 Human Human Integrin alpha L beta 2 (ITGAL&ITGB2) Heterodimer Protein, His Tag&Tag Free
IT2-H53W3-structure
IT2-H53W3-sds
IT2-H53W3-elisa_1

Part of Bioactivity data

IT2-H53W3-SPR
Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag FreeHuman ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) ELISA bioactivity

Immobilized Human ITGAL&ITGB2 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT2-H53W3) at 10 μg/mL (100 μL/well) can bind Human ICAM-1, Fc Tag (Cat. No. IC1-H5250) with a linear range of 0.4-6 ng/mL (QC tested).

Synonym Name

Integrin alpha L beta 2,ITGAL&ITGB2

Background

Integrin alpha-L beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha L beta 2 is also a receptor for F11R (By similarity). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating the role in lymphopoiesis. Integrin alpha L beta 2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lifitegrast SHP-606; SPD-606; SAR-1118; SAR-1119 Approved Shire Development Llc Xiidra United States Dry Eye Syndromes Novartis Pharma Ag 2016-07-11 Keratoconjunctivitis Sicca; Dry Eye Syndromes; Conjunctivitis, Allergic Details

This web search service is supported by Google Inc.

totop